2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Glioblastoma
3
Recurrence
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gliosarcoma
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
156
Gemcitabine
140
Capecitabine
123
Paclitaxel
120
Fluorouracil
117
Oxaliplatin
110
Bevacizumab
106
Nivolumab
99
Leucovorin
97
Docetaxel
97
Cisplatin
89
Radiosurgery
88
Irinotecan
87
Carboplatin
85
Cetuximab
72
Cyclophosphamide
71
Magnetic Resonance Spectroscopy
68
Specimen Handling
60
Radiotherapy
60
Trastuzumab
59
Biopsy
59
Ipilimumab
53
Drug Therapy
51
Everolimus
48
Pemetrexed
46
Albumin-Bound Paclitaxel
45
130-nm albumin-bound paclitaxel
44
Doxorubicin
42
Fulvestrant
40
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts